A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]

This article refers to:

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis

Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.

On page 1763, Figure 4 should be:

Figure 4 Change from baseline in ETDRS score at 12 month study endpoint.

Abbreviation: ETDRS, early treatment in diabetic retinopathy study.